References
- 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2014;35:2541–2619.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
- Alexopoulos D, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Angelidis C, Petousis S, Stakos D, Parissis H, et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome. Am Heart J 2014;167:68–76.
- Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800.
- Wu H, Wang Q, Zhou J, Qian J, Ge J. First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea. Int J Cardiol 2014;176:e127–e128.
- Campo G, Lunghi B, Pavasini R, Ferraresi P, Punzetti S, Malagù M, Biscaglia S, Ferrari R, Bernardi F. Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. Int J Cardiol 2014;177:711–713.
- Tumscitz C, Pirani L, Tebaldi M, Campo G, Biscaglia S. Seven French radial artery access for PCI: A prospective single-center experience. Int J Cardiol 2014;176:1074–1075.
- Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6:1153–1159.
- Judge HM, Buckland RJ, Jakubowski JA, Storey RF. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets 2015: [Epub ahead of print]; doi: 10.3109/09537104.2015.1069809.
- Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016 Jan;13(1):11–27.